{"id":626935,"date":"2025-12-11T20:10:22","date_gmt":"2025-12-11T20:10:22","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/626935\/"},"modified":"2025-12-11T20:10:22","modified_gmt":"2025-12-11T20:10:22","slug":"lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-eli-lilly-and","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/626935\/","title":{"rendered":"Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company – Eli Lilly and Company"},"content":{"rendered":"
    \n
  1. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company<\/a>  Eli Lilly and Company<\/li>\n
  2. Eli Lilly shot helped patients lose 29% of body weight<\/a>  Financial Times<\/li>\n
  3. Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug<\/a>  The New York Times<\/li>\n
  4. Major weight loss, pain relief seen with Eli Lilly’s next-gen drug in late-stage trial<\/a>  Fox Business<\/li>\n
  5. Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial<\/a>  CNBC<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial…\n","protected":false},"author":2,"featured_media":385134,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[105,4326,16,15],"class_list":{"0":"post-626935","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115702754622046798","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/626935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=626935"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/626935\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/385134"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=626935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=626935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=626935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}